Phaseline

Companies › Aribio Lab

Aribio Lab: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease, Vaccines; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CVI-VZV-001
Herpes zoster vaccine
–Phase 2Herpes Zoster; Vaccine-Preventable DiseasesJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06137755CVI-VZV-001Phase 1Vaccine-Preventable DiseasesVaccinesJan 2025
NCT07481604CVI-VZV-001Phase 2Herpes ZosterInfectious diseaseJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Guangzhou Patronus Biotech Dynavax Technologies Cellid Green Cross Osivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.